34th week of 2020 patent applcation highlights part 23 |
Patent application number | Title | Published |
20200262837 | KRAS G12C INHIBITORS - The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor. | 2020-08-20 |
20200262838 | 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30 - The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylatin-enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (I) (I) or a pharmaceutically acceptable salt thereof, wherein R | 2020-08-20 |
20200262839 | CO-CRYSTALS OF RIBOCICLIB AND CO-CRYSTALS OF RIBOCICLIB MONOSUCCINATE, PREPARATION METHOD THEREFOR, COMPOSITIONS THEREOF, AND USES THEREOF - The present invention relates to co-crystals of ribociclib and co-crystals of ribociclib monosuccinate, comprising the co-crystal of ribociclib and saccharin, the co-crystal of ribociclib and cholic acid, the co-crystal of ribociclib and orotic acid, and the co-crystal of ribociclib monosuccinate and citric acid. Compared with the prior art, the co-crystals have one or more improved properties. The present invention also relates to methods of preparing the co-crystal of ribociclib and saccharin, the co-crystal of ribociclib and cholic acid, the co-crystal of ribociclib and orotic acid, and the co-crystal of ribociclib monosuccinate and citric acid, pharmaceutical compositions, and uses thereof in the preparation of medicines for treating and/or preventing diseases involving one or more symptoms of protein kinase related dysfunctions, cancers, transplant rejection and autoimmune diseases. | 2020-08-20 |
20200262840 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY - Provided herein are Heteroaryl Compounds having the following structure: | 2020-08-20 |
20200262841 | ANHYDROUS SUGAR ALCOHOL FLAKES AND MANUFACTURING METHOD THEREFOR - The present invention relates to anhydrous sugar alcohol flakes and a manufacturing method therefor and, more specifically, to a particular form of anhydrous sugar alcohol flakes capable of preventing or mitigating caking occurring during the storage of products, and to a manufacturing method therefor. | 2020-08-20 |
20200262842 | METHODS FOR THE PREPARATION OF 1,3-BENZODIOXOLE HETEROCYCLIC COMPOUNDS - The present invention relates to novel methods for the preparation of 1,3-benzo-dioxole heterocyclic compounds and intermediates for the same. The compounds are useful as PDE4 inhibitors. | 2020-08-20 |
20200262843 | POLYMORPHIC FORM OF TG02 FOR TREATING CANCER - The present disclosure provides crystalline polymorphic forms of TG02 free base and TG02 acid addition salts, pharmaceutical compositions comprising crystalline polymorphic forms of TG02 free base and TG02 acid addition salts, and methods of treating cancer and other diseases in a patient with crystalline polymorphic forms of TG02 free base and TG02 acid addition salts. | 2020-08-20 |
20200262844 | ROCK KINASE INHIBITORS - The present invention relates to compounds that inhibit ROCK activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention. | 2020-08-20 |
20200262845 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS - Compounds of Formula I and methods of use as Interleukin-1 Receptor Associated Kinase 4 (IRAK4) inhibitors are described herein. | 2020-08-20 |
20200262846 | Oligomeric Perylene Diimide Non-Fullerene Acceptors via Direct (Hetero)Arylation Cross-Coupling Reactions - Oligomeric compounds useful as organic conjugated materials in electronic devices. Oligomeric compounds contain three or more or four or more of certain PDI units bonded to an organic core. The organic core contains one, two or more thiophene rings. The organic core can contain two or more thiophene rings separated by a linker group; two or more thiophene rings directly fused to each other or indirectly fused to each other through an optionally substituted aromatic or non-aromatic carbocylic ring system or an optionally substituted aromatic heterocyclic or non-aromatic heterocyclic ring system; or each of two or more thiophene rings is fused to an aromatic or non-aromatic carbocylic ring system or an aromatic heterocyclic or non-aromatic heterocyclic ring system and the resulting fused rings containing a thiophene ring are each separated by a linker group M. Methods for making oligomeric compounds by direct heteroarylation are provided. | 2020-08-20 |
20200262847 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME - The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. | 2020-08-20 |
20200262848 | NOVEL PROCESS FOR THE PREPARATION TAVABOROLE AND ITS INTERMEDIATES - The present invention provides a novel and improved process for the preparation of Tavaborole of Formula (I) and its pharmaceutically acceptable salts. The present invention also provides novel intermediates and process for the preparation of intermediates used in the preparation of Tavaborole. The present invention also provides an improved process for the preparation of Tavaborole and pharmaceutically acceptable salts thereof, that is commercially and industrially scalable. | 2020-08-20 |
20200262849 | HIGH PURITY TRISILYLAMINE, METHODS OF MAKING, AND USE - A composition, comprising: trisilylamine and less than 5 ppmw of halogen. A method of making a silylamine comprising combining ammonia and a compound comprising aminosilane functionality, where the compound comprising aminosilane functionality is according to formula (I) R | 2020-08-20 |
20200262850 | SUBSTITUTED ASYMMETRIC UREAS AS MODULATORS OF GHRELIN RECEPTOR ACTIVITY - Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I: | 2020-08-20 |
20200262851 | INTEGRATED PROCESS FOR THE MANUFACTURE OF METHYLCHLOROHYDRIDOMONOSILANES - The present invention relates to an integrated process for the manufacture of methylchlorohydridomonosilanes in particular, from products of the Müller-Rochow Direct Process. | 2020-08-20 |
20200262852 | CARBIDOPA PRODRUGS - The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease. | 2020-08-20 |
20200262853 | SOLUBLE C5aR ANTAGONISTS - Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): | 2020-08-20 |
20200262854 | RUTHENIUM COMPOUND, RAW MATERIAL FOR FORMING THIN FILM, AND METHOD FOR PRODUCING THIN FILM - A ruthenium compound represented by a general formula described in the specification, a raw material which is for forming a thin film and which contains the ruthenium compound, and a method of producing a thin film using the raw material for forming a thin film are provided. | 2020-08-20 |
20200262855 | MANUFACTURE OF TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] AND COMPOSITIONS THEREOF - The present invention relates to the preparation of compositions comprising sodium trans-[tetrachlorobis(1H-indazole)ruthenate (III)]. Synthesis and formulation preparation is detailed. Impurity profiles are also discussed. Compositions herein are useful for anti-cancer applications. | 2020-08-20 |
20200262856 | UTILITY OF NEMATODE SMALL MOLECULES - The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. In one embodiment, the present invention provides a method of treating an immune and inflammatory disorders disorder by administering a composition comprising a therapeutically effective dosage of an ascaroside compound, or a mixture of ascaroside compounds, or a mixture containing at least one ascaroside. | 2020-08-20 |
20200262857 | NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS - Lysosomally accumulated substances that release a nitroxy group, or a short chain fatty acid or a product of anaerobic metabolism or a thiol or a sulfide often from an ester or similar labile linkage have anti-inflammatory, anti-cancer and anti-bacterial activity. They are useful in treating infectious, inflammatory and malignant disease. | 2020-08-20 |
20200262858 | DERIVATIVES OF AMPHOTERICIN B - Disclosed are derivatives of amphotericin B (AmB) characterized by improved therapeutic index compared to AmB. The AmB derivatives include C16 ureas, carbamates, and amides according to Formula (I); C3′-substituted C16 ureas, carbamates, and amides according to Formula (II); C16 acyls according to Formula (III); C2′epi-C16 ureas, carbamates, and amides according to Formula (IV); and C16 oxazolidinone derivatives according to Formula (V). Also disclosed are pharmaceutical compositions comprising the AmB derivatives, and therapeutic methods of using the AmB derivatives. | 2020-08-20 |
20200262859 | FLOXURIDINE SYNTHESIS - The present invention relates to a process for the preparation of floxuridine. Floxuridine may be useful as an anti-cancer drug. Floxuridine may also be useful in the preparation of other anti-cancer drugs, e.g. NUC-3373. | 2020-08-20 |
20200262860 | NOVEL COMPOUND OF 4'-THIONUCLEOSIDE, AS WELL AS PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF - The present application relates to a method for the prevention or treatment of an abnormal cell proliferative disease in a mammal, wherein the method comprises administering to the mammal an effective amount of a 4′-thionucleoside compound or a pharmaceutically acceptable salt, ester, hydrate, solvate thereof, or racemate thereof, or a mixture thereof. | 2020-08-20 |
20200262861 | GEMCITABINE PRODRUGS - This invention relates to a prodrug of the monophosphate nucleotide of the well-known oncology drug gemcitabine. Specifically, it relates to gemcitabine-[phenyl-benzoxy- | 2020-08-20 |
20200262862 | COMPOUNDS FOR FLUORESCENCE SENSING OF DUPLEX FORMATION - Herein reported are new tricyclic cytidine compounds, such as 8-diethylamino-tC (8-DEA-tC), that respond to DNA and/or RNA duplex formation with up to a 20-fold increase in fluorescent quantum yield as compared with the free nucleoside, depending on neighboring bases. This turn-on response to duplex formation is by far the greatest of any reported nucleoside analogue that can participate in Watson-Crick base pairing. Measurements of the quantum yield of 8-DEA-tC mispaired with adenosine and, separately, opposite an abasic site show that there is almost no fluorescence increase without the formation of correct Watson-Crick hydrogen bonds. Kinetic isotope effects from the use of deuterated buffer show that the duplex protects 8-DEA-tC against quenching by excited state proton transfer. DFT calculations provide a rationale for the observed photophysical properties that is dependent on duplex integrity and the electronic structure of the analogue. | 2020-08-20 |
20200262863 | PREPARATION OF DEOXYCHOLIC ACID - The present invention relates to new and improved processes for the preparation of deoxycholic acid (DCA) and pharmaceutically acceptable salts thereof, as well as to DCA and pharmaceutically acceptable salts thereof, the carbon atoms of which are derived partially or solely from plant sources. | 2020-08-20 |
20200262864 | DEUTERATED FORMS OF AMINOSTEROLS AND METHODS OF USING THE SAME - Described are deuterated forms of aminosterols, or a pharmaceutically acceptable salt thereof, wherein one or more hydrogen atoms at one or more positions selected from C1, C2, C3, C4, C5, C6, C7, C8, C9, C11, C12, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, and C27, are replaced with deuterium. | 2020-08-20 |
20200262865 | COMPOSITIONS AND METHODS FOR TREATING CLOSTRIDIUM ASSOCIATED DISEASES - The present disclosure provides compounds for preventing, treating, and/or reducing the risk of developing a | 2020-08-20 |
20200262866 | PROCESS OF MANUFACTURE OF ANNEXIN V - The present invention provides a process for the recovery and/or purification of a recombinantly expressed intracellular protein comprising the sequence of Annexin A5 (AnxA5) from an endotoxin-producing host cell with a cell wall, wherein the process comprises releasing the intracellular protein from the host cell, characterised in that the step of releasing the intracellular AnxA5 protein is conducted in the presence of a homogenisation buffer comprising non-ionic detergent, and preferably wherein the process does not include any centrifugation steps for the recovery and/or purification of the AnxA5 protein after its release from the host cell and/or in which the AnxA5 protein remains in solution throughout the process except when temporarily bound to any chromatographic resins. | 2020-08-20 |
20200262867 | BCL9 PEPTIDES AND VARIANTS THEREOF - Disclosed here are polypeptides derived from the HD2 domain of human B-cell CLL/lymphoma 9 (BCL9) protein and variants thereof, as well as their use in the diagnosis, prevention, and/or treatment of a disease or disorder. Also disclosed are methods of generating such polypeptides and variants thereof. | 2020-08-20 |
20200262869 | PEPTIDE ANTIBIOTIC COMPLEXES AND METHODS OF USE THEREOF - Provided herein are compounds that form covalent bonds with peptidases, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SPase), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided. | 2020-08-20 |
20200262870 | ANG (1-7) DERIVATIVE OLIGOPEPTIDES AND METHODS FOR USING AND PRODUCING THE SAME - The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and/of impairment. | 2020-08-20 |
20200262871 | SOMATOSTATIN PRODRUGS - The present invention provides prodrugs of somatostatin peptide and peptide analogs that are tissue permeable and oral bioavailable and enable activity of the somatostatin analog at the circulation or target tissue after cleavage of charge-masking lipophilic moieties. Pharmaceutical compositions comprising these prodrugs and their use in therapy and diagnosis are also provided. | 2020-08-20 |
20200262872 | VERTICILIDE ENANTIOMER AND METHODS OF INHIBITING CARDIAC RYANODINE RECEPTOR-MEDIATED INTRACELLULAR CALCIUM RELEASE - The non-natural enantiomer (ent-(+)-verticilide) and uses for treatment of RyR2-mediated spontaneous Ca | 2020-08-20 |
20200262873 | IMMUNOGLOBULIN BINDING PROTEIN, AND AFFINITY SUPPORT USING SAME - Provided are a protein L-derived immunoglobulin binding protein having an increased antibody dissociation rate under acidic conditions, and an affinity support using the same. Disclosed are an immunoglobulin binding protein comprising at least one mutant of an immunoglobulin binding domain, and an affinity support comprising a solid-phase support having the immunoglobulin binding protein bound thereto. A mutant of the immunoglobulin binding domain consists of an amino acid sequence having an identity of at least 85% with the sequence set forth in any one of SEQ ID NO:1 to SEQ ID NO:9 and a predetermined mutation, and the mutant has immunoglobulin κ chain binding activity. | 2020-08-20 |
20200262874 | INSECTICIDAL PROTEINS AND METHODS FOR THEIR USE - Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein. In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus, transformed bacteria, plants, plant cells, plant tissues and seeds are provided. Compositions are insecticidal nucleic acids and proteins of bacterial species. The sequences find use in the construction of expression vectors for subsequent transformation into organisms of interest including plants, as probes for the isolation of other homologous (or partially homologous) genes. The pesticidal proteins find use in controlling, inhibiting growth or killing Lepidopteran, Coleopteran, Dipteran, fungal, Hemipteran and nematode pest populations and for producing compositions with insecticidal activity. | 2020-08-20 |
20200262875 | Host cells and methods using a repressor polypeptide and an inducible promoter for gene expression - The present invention provides for a system comprising (a) a first nucleic acid comprising a nucleotide sequence encoding a nucleotide sequence of interest operatively linked to a promoter comprising a repressor polypeptide binding site, and (b) a second nucleic acid comprising a nucleotide sequence encoding a repressor polypeptide having at least 70% amino acid identity with EilR, SmvR, KmrR, RcdA, or QacR; wherein expression of the nucleotide sequence of interest from the promoter is induced by the presence of a hydrophobic inducer, such as a hydrophobic cation inducer, such as a triarylmethane, acridine, phenazine, phenothiazine, or xanthene. | 2020-08-20 |
20200262876 | Novel Insect Inhibitory Proteins - Pesticidal proteins exhibiting toxic activity against Lepidopteran pest species are disclosed, and include, but are not limited to, TIC4472, TIC4472PL, TIC1425, TIC2613, and TIC2613PL. DNA constructs are provided which contain a recombinant nucleic acid sequence encoding one or more of the disclosed pesticidal proteins. Transgenic plants, plant cells, seed, and plant parts resistant to Lepidopteran infestation are provided which contain recombinant nucleic acid sequences encoding the pesticidal proteins of the present invention. Methods for detecting the presence of the recombinant nucleic acid sequences or the proteins of the present invention in a biological sample, and methods of controlling Lepidopteran species pests using any of the TIC4472, TIC4472PL, TIC1425, TIC2613, and TIC2613PL pesticidal proteins are also provided. | 2020-08-20 |
20200262877 | ION CHANNEL-BINDING PEPTIDES AND METHODS OF USE THEREOF - Disclosed herein are compositions and methods of use comprising peptides that bind to ion channels. Such peptides can function as active agents that target ion channels to inhibit or activate ion channels in a target tissue or cell type. In some embodiments, such peptides can be conjugated to another active agent or a detectable label. | 2020-08-20 |
20200262878 | Compositions and Methods of Use for Recombinant Human Secretoglobins - Methods of synthetically producing, formulating and using secretoglobins SCGB1A1, SCGB3A2, and SCGB3A1 are provided. Methods of using secretoglobins SCGB1A1, SCGB3A2, and SCGB3A1 as therapeutic agents to affect long term patient outcomes, such as preventing severe respiratory exacerbations of underlying conditions that require medical intervention, including hospitalization are provided. Methods of producing recombinant human secretoglobins, analytical methods, pharmaceutical compositions, and methods of use to prevent the long term sequelae of acute and chronic respiratory conditions are provided. | 2020-08-20 |
20200262879 | METHODS AND COMPOSITIONS TO ENHANCE THE IMMUNOGENICITY OF TUMORS - Methods and compositions for enhancing the immunogenicity of a tumor of interest by modulating/altering the expression of specific complement proteins and complement protein receptors associated with the immune suppression of a tumor/tumor cell are described herein. | 2020-08-20 |
20200262880 | PEPTIDES WITH ANTIBIOTIC POTENTIAL AGAINST MYCOBACTERIUM TUBERCULOSIS - The present invention relates to isolated variants of an antimicrobial peptide plectasin, comprising a substitution at positions 9, 13 and 32, wherein the variant has antimicrobial activity and methods for treatment of treatment of diseases mediated by | 2020-08-20 |
20200262881 | pHLIP-Mediated Carbohydrate Tethering at Cell Surfaces to Induce Immune Response - The invention features a compositions and methods for inducing an immune response to targeted cells. The compositions induce targeting of a cell by positioning carbohydrate epitopes on the surface of the cell by conjugation of the epitope to a pH-triggered membrane peptide (pHLIP®). | 2020-08-20 |
20200262882 | MODIFIED GAL-1 PROTEINS AND USES THEREOF - Described herein are modified gall monomers that can contain one or more mutated cysteines and/or can be pegylated. Also described herein are modified gall dimers, trimers, and tetramers that can contain one or more modified gall monomers as described herein. Also described herein are pharmaceutical formulations containing a modified gall monomer, dimer, trimer, and/or tetramer. Also described herein are methods of making the modified gall polypeptides and complexes thereof. Also described herein are methods of using the modified gall polypeptides and complexes thereof. | 2020-08-20 |
20200262883 | CELL LINE WHICH IS KNOCK OUT THE BMP RECEPTOR GENES AND A METHOD OF PRODUCING TARGET PROTEINS USING THE SAME - The present invention relates to a transgenic CHO cell line in which the BMP receptor gene BMPRIA or BMPRII is knocked out. The BMP type I receptor BMPRIA or BMP type II receptor BMPRII gene which plays an important role in intracellular signal transduction in CHO cells is knocked out to prevent the activation of self concentration control pathway and the signal transduction mediated by BMP in CHO cells, so that the productivity of a target protein to be produced can be improved. | 2020-08-20 |
20200262884 | TARGETED MODIFIED TNF FAMILY MEMBERS - The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains can-y one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases. | 2020-08-20 |
20200262885 | SELECTIVE GLUCAGON RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING PURPOSES - The present invention relates to exendin-4 peptide analogues which selectively bind and activate the glucagon receptor and comprise a chelating moiety capable of binding a metal ion and their use, for example in PET imaging. | 2020-08-20 |
20200262886 | CHEMO-ENZYMATIC SYNTHESIS OF SEMAGLUTIDE, LIRAGLUTIDE AND GLP-1 - The invention relates to a method for preparing a coupling product having the sequence P | 2020-08-20 |
20200262887 | OXYNTOMODULIN PEPTIDE ANALOG FORMULATIONS - The present invention relates to GLP-1 and/or glucagon receptor agonists (for example, oxyntomodulin peptide analogs), pharmaceutically acceptable salts thereof, formulations comprising the same, and uses thereof for treating diabetes and/or obesity or associated diseases or disorders. | 2020-08-20 |
20200262888 | LONG-ACTING CONJUGATES OF GLP-2 DERIVATIVES - A glucagon-like peptide-2 (GLP-2) derivative, a conjugate thereof, and a use thereof are disclosed. Additionally, a method for preparing a glucagon-like peptide-2 (GLP-2) derivative and a conjugate thereof is disclosed. | 2020-08-20 |
20200262889 | SUCCINATE-BINDING POLYPEPTIDES AND USE THEREOF - Polypeptides comprising an amino acid sequence of Slc26a6 or IRBIT comprising a mutation that increases NaDC-1 binding, stability of the polypeptide, stability of NaDC-1 complex or a combination thereof are provided. Polypeptides comprising an amino acid sequence of a mutant succinate receptor 1 (mutSUCNR1), comprising a mutation that increases succinate binding, stability of the polypeptide, stability of the mutSUCNR1-succinate complex or combinations thereof are also provided. Compositions comprising the polypeptides, nucleic acid molecules and vectors encoding the polypeptides, and methods of use of the polypeptides or compositions, specifically for treating succinate-associate diseases and conditions are also provided. | 2020-08-20 |
20200262890 | ENGINEERED POLYPEPTIDES - Provided herein are polypeptides that bind to a blood-brain barrier (BBB) receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a BBB receptor-expressing cell, e.g., for transport across the BBB. Also provided herein are transferrin receptor (TfR) constructs that comprise a monomeric TfR apical domain or one or more portions of the TfR apical domain which have been circularly permuted relative to the full-length TfR sequence. | 2020-08-20 |
20200262891 | CD33 EXON 2 DEFICIENT DONOR STEM CELLS FOR USE WITH CD33 TARGETING AGENTS - Disclosed herein are compositions and methods relating to agents that target a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies. | 2020-08-20 |
20200262892 | METHOD AND DEVICE FOR FAST DISSOLUTION OF SOLID PROTEIN COMPOSITION - Provided are methods and devices for dissolving solid protein compositions, such as solid compositions comprising fibrinogen, in an aqueous solvent. The methods comprise use of a closed container containing a volume of solid fibrinogen composition and a head space wherein the pressure within the headspace is sub-atmospheric. Aqueous solvent is introduced into the container while maintain the sub-atmospheric pressure, and subsequent to addition of the solvent, the size of the headspace is decreased to bring the pressure to atmospheric pressure. The devices are suitable for use in the disclosed method. | 2020-08-20 |
20200262893 | GLYPICAN-3-BINDING FIBRONECTIN BASED SCAFFOLD MOLECULES - Provided herein are polypeptides which include tenth fibronectin type III domains ( | 2020-08-20 |
20200262894 | STREP-TAG SPECIFIC BINDING PROTEINS AND USES THEREOF - The present disclosure provides immunoglobulin binding proteins and fusion proteins that specifically bind to a strep tag peptide, such as a peptide having the amino acid sequence set forth in SEQ ID NO: 19. Also provided are methods for using the disclosed compositions in a cellular immunotherapy wherein the therapeutic cells express a tag peptide. | 2020-08-20 |
20200262895 | HUMAN ANTI-TAU ANTIBODIES - Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively. | 2020-08-20 |
20200262896 | MELANIN ANTIBODIES AND USES THEREOF - Provided herein are monoclonal antibodies that specifically bind to melanin. The antibodies may be chimeric or humanized. Also provided herein are methods of use and methods of making the antibodies described. For example, the melanin antibodies may be used therapeutically to treat or prevent melanoma. | 2020-08-20 |
20200262897 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF PATIENTS WITH MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS - Provided are methods for clinical treatment of Membranoproliferative glomerulonephritis (MPGN) by administering an anti-C5 antibody, or antigen binding fragment thereof. | 2020-08-20 |
20200262898 | ANTIBODIES COMPRISING A COMMON LIGHT CHAIN AND USES THEREOF - Peptides and uses thereof, such as a common light chain in an antibody, are provided. | 2020-08-20 |
20200262899 | Fc VARIANTS WITH ALTERED BINDING TO FcRn - The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index. | 2020-08-20 |
20200262900 | ANTI-C5 ANTIBODIES AND USES THEREOF - The present invention provides monoclonal antibodies that bind to the complement factor 5 (C5) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to C5 protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing C5 activity, thus providing a means of treating or preventing a C5-related disease or disorder in humans. In some embodiments, the invention provides for an anti-C5 antibody that has improved pharmacokinetic and pharmacodynamic properties, e.g., a half-life of more than 10 days. | 2020-08-20 |
20200262901 | ANTI-C5 ANTIBODIES AND USES THEREOF - The present invention provides monoclonal antibodies that bind to the complement factor 5 (C5) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to C5 protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing C5 activity, thus providing a means of treating or preventing a C5-related disease or disorder in humans. In some embodiments, the invention provides for an anti-C5 antibody that has improved pharmacokinetic and pharmacodynamic properties, e.g., a half-life of more than 10 days. | 2020-08-20 |
20200262902 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF - Antibodies to human N3pGlu Aβ, compositions comprising such N3pGlu Aβ antibodies, and methods of using such N3pGlu Aβ antibodies for the treatment of a disease characterized by deposition of Aβ including clinical or pre-clinical Alzheimer's disease, Down's syndrome, and clinical or pre-clinical cerebral amyloid angiopathy. | 2020-08-20 |
20200262903 | Treatment of age-related macular degeneration - A means of treating both the “dry” and/or “wet” forms of Age-Related Macular Degeneration (ARMD) using a disease targeting drug delivery system in which an anti-inflammatory drug is incorporated into nanoparticles such as liposomes, micelles, dendrimers, lipid nanospheres, nanoemulsions and the like. The nanoparticles are coated with an anti-Vascular Endothelial Growth Factor Receptor (VEGFR) targeting agent such as anti-VEGFR antibodies, anti-VEGFR aptamers, anti-VEGFR binding peptides and the like. Upon administration into the eye of a patient with ARMD the targeting agent on the nanoparticle will bind to VEGFR on neovascular cells in the retina and inhibit the abnormal proliferation of new blood vessels. In addition to its therapeutic action the targeting agent by binding to its receptor will anchor the drug delivery vehicle at the site of inflammation where the anti-inflammatory drug is released for maximum effect in inhibiting the local inflammatory response. | 2020-08-20 |
20200262904 | ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2 - The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2020-08-20 |
20200262905 | DUAL PDGF/VEGF ANTAGONISTS - The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration. | 2020-08-20 |
20200262906 | ANTIBODIES AGAINST PHOSPHORYLCHOLINE IN COMBINATION THERAPY WITH BIOLOGIC AGENTS - Antibodies against PC, PC conjugate or bioactive components and/or fragments thereof for use in combination therapy with one or more biologic agents and/or stem cells are disclosed, as well as compositions comprising the antibodies in combination with one or more biologic agents and/or stem cells. Also disclosed are PC conjugates, PC or bioactive components and/or parts/fragments thereof for use in activation immunotherapy prior to or in combination with treatment with biologic agents and/or stem cells for curing, treating, preventing, and/or reducing the risk of developing auto-immune diseases, chronic inflammatory diseases, and cancer diseases, as well as compositions comprising them in combination with biologic agents and/or stem cells. | 2020-08-20 |
20200262907 | CCL20 AS A PREDICTOR OF CLINICAL RESPONSE TO IL23-ANTAGONISTS - The present invention relates to the use of the Chemokine (C—C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2). | 2020-08-20 |
20200262908 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IL-12/IL-23 INHIBITOR RELEASED USING AN INGESTIBLE DEVICE - This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an IL-12/IL-23 inhibitor. | 2020-08-20 |
20200262909 | IL-5 ANTIBODY, ANTIGEN BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREFOR - Provided are an IL-5 antibody, an antigen binding fragment thereof, and a medical application therefor. The present invention comprises a mouse-derived antibody containing an IL-5 antibody CDR region, a chimeric antibody, a humanized antibody, and a pharmaceutical composition comprising said IL-5 antibody and said antigen binding fragment thereof, as well as the use of the pharmaceutical composition as a drug. | 2020-08-20 |
20200262910 | TREATMENT OF HEPATOTOXICITY - Methods of treating and preventing hepatotoxicity through inhibiting interleukin 11 (IL-11)-mediated signalling are disclosed, as well as agents for use in such methods. | 2020-08-20 |
20200262911 | THERAPEUTIC ANTIBODY FORMULATION - Stable aqueous pharmaceutical formulations for therapeutic antibodies and methods of using such stable aqueous pharmaceutical formulations. | 2020-08-20 |
20200262912 | ANTI-IL-25 ANTIBODIES AND USES THEREOF - The present invention provides antibodies that bind to human interleukin-25 (IL-25) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human IL-25 with high affinity. In certain embodiments, the invention includes antibodies that bind human IL-25 and block IL-25-mediated cell signaling. The antibodies of the invention may be fully human, non-naturally occurring antibodies. The antibodies of the invention are useful for the treatment of various disorders associated with IL-25 activity or expression, including asthma, allergy, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, atopic dermatitis (AD), and Eosinophilic Granulomatosis with Polyangiitis (EGPA), also know as Churg-Strauss Syndrome. | 2020-08-20 |
20200262913 | METHODS OF TREATING PRURITIC DISEASE WITH IL-31 MONOCLONAL ANTIBODIES - The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31. | 2020-08-20 |
20200262914 | PEPTIDES SELECTIVE FOR BCL-2 FAMILY PROTEINS - Provided herein are peptides selective for combinations of Mcl-1/Bfl-1/Bc1-xL. Also provided are compositions containing these polypeptides and methods of using such peptides in the treatment of cancer that include administering to a subject one of the polypeptides. | 2020-08-20 |
20200262915 | CLAUDIN 6 ANTIBODIES AND USES THEREOF - Antibodies and compositions against Claudin 6 and uses thereof are provided. | 2020-08-20 |
20200262916 | Mammalian Atg8 Proteins Control Autolysosomal Biogenesis Through SNARES - The present invention is directed to the elucidation of the mechanism that human Atg8 protein regulates endolysosomal systems in the cell and the role this protein plays in mediating autophagy. Methods of treating autophagy-mediated disease states with agonists/antagonists of Atg8, STX16 and STX17 proteins are disclosed as are pharmaceutical compositions. | 2020-08-20 |
20200262917 | COMPOSITION FOR CYTOTOXIC T CELL DEPLETION - Provided is a novel composition. Provided is a composition for cytotoxic T cell depletion, comprising an anti-LAG-3 antibody or a binding fragment thereof having the properties described in (i) to (iii) below: (i) having in vitro ADCC activity; (ii) reducing, in a low fucose form, the number of LAG-3 positive cells in vivo; and (iii) binding to activated human T cells. | 2020-08-20 |
20200262918 | Disrupting FC Receptor Engagement on Macrophages Enhances Efficacy of Anti-SIRPalpha Antibody Therapy - Anti-SIRPα antibodies, including multi-specific anti-SIRPα antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRPα and can block the interaction of CD47 on one cell with SIRPα on a phagocytic cell. The subject anti-SIRPα antibodies find use in various therapeutic methods. Embodiments of the disclosure include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the anti-SIRPα antibodies; and cell lines that produce the antibodies. Also provided are amino acid sequences of exemplary anti-SIRPα antibodies. | 2020-08-20 |
20200262919 | COMPOSITIONS AND METHODS FOR TREATING DIFFUSE LARGE B CELL LYMPHOMA - Methods and compositions for treating diffuse large B cell lymphoma (DLBCL) using a combination of blinatumomab and/or a blinatumomab variant and pembrolizumab, a pembrolizumab variant and/or an antigen-binding fragment thereof, are provided. | 2020-08-20 |
20200262920 | DOSING REGIMEN FOR CD3 BINDING PROTEINS - Described herein are bispecific binding proteins that specifically bind to an antigen expressed on a target cell and an antigen expressed on a T-cell, e.g., human CD33 and human CD3 and therapeutically effective dosing regimens for immunotherapy of cancers, diseases and conditions such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and solid tumor cancers. | 2020-08-20 |
20200262921 | CTLA-4 ANTIBODIES AND USES THEREOF - Human antibodies which specifically bind to human CTLA-4, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. | 2020-08-20 |
20200262922 | STABLE FORMULATIONS OF ANTI-CTLA4 ANTIBODIES ALONE AND IN COMBINATION WITH PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF - The invention relates to stable formulations comprising antibodies or antigen binding fragments thereof that bind to cytotoxic T lymphocyte associated antigen 4 (CTLA4), optionally further containing an anti-human programmed death receptor 1 (PD-1) antibody or antigen binding fragment thereof. Also provided are methods of treating various cancers and chronic infections with the formulations of the invention. | 2020-08-20 |
20200262923 | METHODS FOR TARGETING THE IMMUNE CHECKPOINT PD1 PATHWAY FOR TREATING PULMONARY FIBROSIS - The invention relates to methods for treating or preventing progressive pulmonary fibrosis in a subject. | 2020-08-20 |
20200262924 | PHARMACEUTICAL COMPOSITION ADMINISTERED IN COMBINATION WITH SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND AND IMMUNOTHERAPEUTIC AGENT - A pharmaceutical composition including a compound represented by the formula (I) or a pharmacologically acceptable salt thereof wherein two R moieties each independently are a C | 2020-08-20 |
20200262925 | Combination Therapy For Treatment Of B-Cell Malignancies - Provided herein are methods of treating a B-cell malignancy, and gene mutations that can be used to identify subjects who will be responsive to treatment of a B-cell malignancy with a combination of ibrutinib and an anti-PD-1 antibody. | 2020-08-20 |
20200262926 | MULTISPECIFIC BINDING PROTEINS WITH MUTANT FAB DOMAINS - Binding proteins comprising a VL region paired with a VH region, and a CH1 region paired with a CL region, wherein the VL region and VH region comprise opposite charged mutations to facilitate pairing, and wherein the CH1 region and CL region comprise mutations to facilitate pairing, are provided. Binding proteins comprising one or more cysteine residues engineered into the VH/VL pair to form one or more disulfide bonds, are also provided. Multispecific binding proteins, nucleic acids encoding binding proteins and multispecific binding proteins, expression vectors, host cells, pharmaceutical composition and methods of treatment administering the binding proteins or multispecific binding proteins described herein are also provided. | 2020-08-20 |
20200262927 | ANTIBODIES AND METHODS OF USE - Disclosed herein are antibodies directed against CRTAM, nucleic acids encoding such antibodies, host cells comprising such nucleic acids encoding the antibody, methods for preparing anti-CRTAM antibodies, and methods for the treatment of diseases, e.g., human cancers, including but not limited to small cell lung cancer, non-small cell lung cancer (including squamous carcinomas and adenocarcinomas) skin cancer including melanoma, breast cancer (including TNBC), colorectal cancer, gastric cancer, ovarian cancer, cervical cancer, prostate cancer, kidney cancer, liver cancer including hepatocellular carcinoma, pancreatic cancer, head and neck cancer, nasopharyngeal cancer, oesophageal cancer, bladder cancer and other uroepithelial cancers, stomach cancer, glioma, glioblastoma, testicular, thyroid, bone, gallbladder and bile ducts, uterine, adrenal cancers, sarcomas, GIST, neuroendocrine tumours, and haematological malignancies. | 2020-08-20 |
20200262928 | ANTI-MSLN ANTIBODY AND PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT COMPRISING SAME - The present invention relates to an anti-MSLN antibody and a pharmaceutical composition for cancer treatment comprising same. The anti-MSLN antibody according to the present invention has high affinity and specificity for MSLN and thus can be effectively used in cancer prevention or treatment. | 2020-08-20 |
20200262929 | ANTI-CD146 ANTIBODIES AND USES THEREOF - The present invention relates to the field of diagnostic and treatment of cancer, particularly melanoma, pancreatic cancer, kidney cancer and colon cancer. In particular, the invention relates to an antibody directed specifically to CD146-positive tumors and its applications, particularly for use as a medicament for the prevention and/or treatment of cancer, for use in a method of diagnostic or prognostic of a cancer, or for use as a radiotracer when labelled with a radioactive element. | 2020-08-20 |
20200262930 | ANTI-YKL40 ANTIBODIES AND METHODS OF USE - This invention relates to selective inhibition of inflammation using an anti-YKL-40 antibody. Specifically, the invention relates to methods of treating an inflammatory disease or inflammatory disorder in an individual by contacting the individual with an anti-YKL-40 antibody. | 2020-08-20 |
20200262931 | METHODS AND APPARATUS FOR FALSE POSITIVE MINIMIZATION IN FACIAL RECOGNITION APPLICATIONS - An apparatus can include a processor that can receive location data from a user device, and store the location data in a user profile data structure also storing facial recognition data. The processor can also receive at least one image, and can identify a location based at least in part on a set of characteristics within the at least one image. The processor can, for each user profile data structure stored in a database, compare location data in that user profile data structure to the location. The processor can, when the location data of the user profile data structure and the location match, conduct facial recognition to determine whether the user associated with the user profile data structure can be identified in the at least one image. The processor can then associate the at least one image with the user profile data structure if the user can be identified. | 2020-08-20 |
20200262932 | HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF - Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins | 2020-08-20 |
20200262933 | CELLULOSE ACETATE AND METHOD FOR PRODUCING CELLULOSE ACETATE - Provided is cellulose acetate with which a hollow fiber membrane having excellent salt rejection and water permeability can be produced. The cellulose acetate, in which a total content of calcium and magnesium is 2.8 to 3.5 μmol/g; a 6 percent viscosity is 40 to 80 mPa⋅s; a degree of filtration Kw is 35 g | 2020-08-20 |
20200262934 | METHYL-ETHYL-HYDROXYALKYL-CELLULOSE AND ITS USE IN BUILDING COMPOSITIO - A methyl ethyl hydroxyalkyl cellulose (MEHEC), process for making the MEHEC, and a powder containing the MEHEC are disclosed. The MEHEC is provided with a DSmethyl from 1.5 to 2.5, a DSethyl from 0.005 to 0.15, and a MSalkylene-oxide from 0.005 to 0.2. The methyl ethyl hydroxyalkyl cellulose optionally includes an anti-oxidant. The MEHEC optionally does not have a combination of a DSmethyl of 2.2 or 1.8, a DSethyl of 0.05 or 0.1, and a MSalkylene-oxide of 0.1 and does not have a combination of a DSmethyl of 2.5 or 2.0, a DSethyl of 0.1, and a MSalkylene-oxide of 0.05. The MEHEC has very good biostability and is suitable for use in the building industry. | 2020-08-20 |
20200262935 | SWELLING OF STARCH SUSPENSIONS - A methodology useful for predicting the texture of a heated starch suspension by predicting the storage modulus (G′) of the starch suspension resulting from starch granule swelling during heating has been developed. The methodology is based on the physical properties of the starch granules in the starch suspension and the temperature history of the heated starch suspension. | 2020-08-20 |
20200262936 | CHARGE-BEARING CYCLODEXTRIN POLYMERIC MATERIALS AND METHODS OF MAKING AND USING SAME - The present disclosure relates to charge-bearing polymeric materials and methods of their use for purifying fluid samples from micropollutants, such as anionic micropollutants. | 2020-08-20 |
20200262937 | HIGH MOLECULAR WEIGHT CHITOSAN, PROCESS FOR OBTAINING AND USES THEREOF - The present disclosure relates to a method for obtaining a high molecular weight chitosan with a lower acetylation degree and its use in human or veterinarian medicine. More specifically, to the obtaining of this biomaterial by means of a simpler process, with reduced energy costs, when compared with conventional procedures. | 2020-08-20 |